SVRA
Savara Inc.
$5.09
-$0.12(-2.30%)
40
Overall
50
Value
36
Tech
36
Quality
Market Cap
$686.16M
Volume
2.94M
52W Range
$1.89 - $7.01
Target Price
$10.94
Company Overview
| Mkt Cap | $686.16M | Price | $5.09 |
| Volume | 2.94M | Change | -2.30% |
| P/E Ratio | -5.8 | Open | $5.18 |
| Revenue | -- | Prev Close | $5.21 |
| Net Income | $-118.8M | 52W Range | $1.89 - $7.01 |
| Div Yield | N/A | Target | $10.94 |
| Overall | 40 | Value | 50 |
| Quality | 36 | Technical | 36 |
No chart data available
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)
TipRanks Auto-Generated Intelligence Newsdesk•12 days ago
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Encompass Health (EHC) and SI-Bone (SIBN)
Catie Powers•15 days ago
Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)
TipRanks Auto-Generated Intelligence Newsdesk•24 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SVRA | $5.09 | -2.3% | 2.94M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |